FOXO4-DRI
FOXO4-DRI represents a breakthrough in senolytic peptide research, offering a targeted approach to cellular rejuvenation and healthy aging. By selectively eliminating senescent cells, this peptide has become a leading tool in longevity and regenerative medicine studies, paving the way for new strategies in combating age-related decline.
$350.00
This product remains in its original powdered state without being reconstituted.
Senolytic Peptide for Cellular Regeneration and Longevity Research
Overview
FOXO4-DRI is a synthetic D-retro-inverso peptide designed to selectively induce apoptosis in senescent (aging) cells, which accumulate over time and contribute to tissue dysfunction, inflammation, and aging-related decline. By disrupting the interaction between FOXO4 and p53, FOXO4-DRI allows aged or damaged cells to undergo programmed cell death, promoting cellular renewal and tissue rejuvenation.
Mechanism of Action
In normal aging, FOXO4 binds to p53 in senescent cells, preventing them from dying and allowing dysfunctional cells to persist. FOXO4-DRI works by blocking this FOXO4–p53 interaction, releasing p53 and triggering selective apoptosis in senescent cells—without harming healthy, dividing cells.
This mechanism supports:
-
Clearing senescent cells that drive inflammation and tissue aging
-
Enhancing stem cell function and tissue repair
-
Improving mitochondrial health and energy metabolism
-
Supporting overall longevity and vitality
Key Research Areas
-
Cellular senescence and aging biology
-
Tissue regeneration and longevity research
-
Mitochondrial and metabolic health
-
Anti-inflammatory and age-related disease models
PRODUCTS ARE FOR RESEARCH PURPOSES ONLY
Related Products
Related products
